Literature DB >> 9114915

Effect on dietary fat absorption of orlistat, administered at different times relative to meal intake.

D Hartmann1, Y Hussain, C Güzelhan, J Odink.   

Abstract

Orlistat (O) is a potent and selective inhibitor of gastrointestinal lipases. The effect on dietary fat absorption following dosing of O at different times relative to meals was investigated in a placebo (P) controlled study in 24 hospitalized healthy males. After a 5-day run-in, to accustom the subjects to a diet of 2400 kcal and 77 g fat per day and to establish baseline faecal fat excretion, subjects received, in four parallel groups of 6. over 8 days three times daily doses of 80 mg O.P.P (group A) or P. 80 mg O.P (group B) or P.P. 80 mg O (group C) or P.P.P (group D) at mid-meal. 1 h and 2 h after mid-meal respectively. Faeces were collected to measure total fat excretion. The mean (s.d.) of faecal fat in percent of dietary fat, after deduction of pre-treatment faecal fat, was (%) 32.8 (8.1), 34.0 (8.8), 26.9 (4.0) and -1.4 (1.7) in groups A. B. C and D respectively. It was concluded that, within the time period investigated, the pharmacological effect of O is not critically dependent on the time of dosing relative to meals.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 9114915      PMCID: PMC1364649          DOI: 10.1111/j.1365-2125.1993.tb04228.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  7 in total

1.  Treating obesity.

Authors:  J S Garrow
Journal:  BMJ       Date:  1991-04-06

2.  More on chewing the fat. The good fat and the good cholesterol.

Authors:  F M Sacks; W W Willett
Journal:  N Engl J Med       Date:  1991-12-12       Impact factor: 91.245

3.  Gastric emptying and secretion of bile acids, cholesterol, and pancreatic enzymes during digestion. Duodenal perfusion studies in healthy subjects.

Authors:  H Brunner; T C Northfield; A F Hofmann; V L Go; W H Summerskill
Journal:  Mayo Clin Proc       Date:  1974-11       Impact factor: 7.616

4.  Mode of action of tetrahydrolipstatin: a derivative of the naturally occurring lipase inhibitor lipstatin.

Authors:  B Borgström
Journal:  Biochim Biophys Acta       Date:  1988-10-14

5.  Studies on the antiobesity activity of tetrahydrolipstatin, a potent and selective inhibitor of pancreatic lipase.

Authors:  S Hogan; A Fleury; P Hadvary; H Lengsfeld; M K Meier; J Triscari; A C Sullivan
Journal:  Int J Obes       Date:  1987

6.  Gastric processing and emptying of fat.

Authors:  J H Meyer; E A Mayer; D Jehn; Y Gu; A S Fink; M Fried
Journal:  Gastroenterology       Date:  1986-05       Impact factor: 22.682

7.  Inhibition of pancreatic lipase in vitro by the covalent inhibitor tetrahydrolipstatin.

Authors:  P Hadváry; H Lengsfeld; H Wolfer
Journal:  Biochem J       Date:  1988-12-01       Impact factor: 3.857

  7 in total
  6 in total

1.  Influence of orlistat on the regulation of gallbladder contraction in man: a randomized double-blind placebo-controlled crossover study.

Authors:  F Froehlich; D Hartmann; C Guezelhan; J J Gonvers; J B Jansen; M Fried
Journal:  Dig Dis Sci       Date:  1996-12       Impact factor: 3.199

Review 2.  Limitations in anti-obesity drug development: the critical role of hunger-promoting neurons.

Authors:  Marcelo O Dietrich; Tamas L Horvath
Journal:  Nat Rev Drug Discov       Date:  2012-08-03       Impact factor: 84.694

Review 3.  Orlistat: a review of its use in the management of obesity.

Authors:  K M Hvizdos; A Markham
Journal:  Drugs       Date:  1999-10       Impact factor: 9.546

Review 4.  Orlistat.

Authors:  W McNeely; P Benfield
Journal:  Drugs       Date:  1998-08       Impact factor: 9.546

5.  Clinical and economic considerations of antiobesity treatment: a review of orlistat.

Authors:  Armineh Zohrabian
Journal:  Clinicoecon Outcomes Res       Date:  2010-07-05

Review 6.  When fat meets the gut-focus on intestinal lipid handling in metabolic health and disease.

Authors:  Magdalena Wit; Jonathan Trujillo-Viera; Akim Strohmeyer; Martin Klingenspor; Mohammed Hankir; Grzegorz Sumara
Journal:  EMBO Mol Med       Date:  2022-04-19       Impact factor: 14.260

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.